98
Participants
Start Date
March 3, 2023
Primary Completion Date
March 26, 2025
Study Completion Date
June 23, 2025
TIN816
TIN816
Placebo
Placebo
Novartis Investigative Site, Leuven
Novartis Investigative Site, Genk
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Pécs
Novartis Investigative Site, Taipei
Novartis Investigative Site, Santiago de Compostela
Duke Univ Medical Center, Durham
Novartis Investigative Site, Madrid
Novartis Investigative Site, Rennes
Novartis Investigative Site, Nantes
Novartis Investigative Site, Essen
Novartis Investigative Site, Tartu
Novartis Investigative Site, Paris
Mayo Clinic Phoenix, Phoenix
Novartis Investigative Site, Poitiers
Novartis Investigative Site, Neuilly-sur-Seine
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Singapore
Novartis Investigative Site, Lucknow
Novartis Investigative Site, Ahmedabad
Novartis Investigative Site, CABA
Novartis Investigative Site, CABA
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Salvador
Novartis Investigative Site, Montreal
Novartis Investigative Site, Montreal
Novartis Investigative Site, Montreal
Novartis Investigative Site, Québec
Novartis Investigative Site, Ostrava
Novartis Investigative Site, Dresden
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Budapest
Novartis Investigative Site, Budapest
Novartis Investigative Site, Vilnius
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Badalona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY